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Efficacy and Safety of Nebulized Recombinant Human DNase as Rescue 
Treatment for Persistent Atelectasis in Newborns: Case-series
Aim To evaluate the efficacy and safety of using recombinant human 
DNase (rhDNase) in diminishing persistent atelectasis unresponsive to 
conventional treatment and mucus plugging in newborns with insuffi-
cient ability to clear thick and purulent airway secretions.
Methods Twelve newborns (10 preterms), who did not respond to con-
ventional methods, received rhDNase nebulized therapy at a dose of 1.25 
mg over a 15-minute period, twice a day (2 hours between the doses) 
for up to 3 days. The application of the drug was continued for up to 3 
days or until the improvement of atelectasis. After a-three-day therapy, if 
atelectasis did not improve, a single dose (1.25 mg) of the same drug in 
liquid form was administered endotracheally. Clinical (respiration rate, 
requirement for oxygen concentration) and radiological response (chest 
x-ray scoring), duration of the treatment, recurrence of atelectasis and 
requirement for additional therapy were evaluated.
Results Ten out of 12 patients showed rapid clinical and radiological im-
provement after nebulized treatment. Two patients who did not respond 
to the three-day regimen received a single dose of the drug endotracheally 
and both recovered completely. Six patients did not require completion 
of three day regimen for radiological recovery. Chest x-ray scores and 
respiratory parameters showed significant improvement after the treat-
ment. The respective median (range) values before and after treatment 
were 4 (1-5) and 0 (0-4) points for chest x-ray scores, 66 (60-78) and 
49 (44-64) breaths/min for respiratory rates, and 45% (35-64) and 30% 
(21-40) for oxygen requirement. Comparison of pCO2 before (median, 
56 mm Hg; range, 46-64) and after treatment (median, 41 mm Hg; range 
38-58) in 7 patients showed significant improvement.
Conclusion In a large series of newborns to receive rhDNase and we 
demonstrated the usefulness of rhDNase as a mucolytic agent in treating 
newborns with persistent atelectasis who do not respond to other treat-
ments.
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Inflammatory response in the airway leads to 
the necrosis of the respiratory epithelium and 
sloughing into the airway lumen. Also, tissue 
edema and mucus production occur, resulting 
in the formation of thick mucous plugs within 
the airway lumen. This process leads to a disrup-
tion of the normal airflow (1). Some airways be-
come partially or completely occluded, leading 
to air trapping and hyperinflation or atelectasis 
(2). Due to the lysis of inflammatory cells, there 
are large amounts of DNA present in the mu-
cous plugs. DNA is a polyanion molecular com-
pound that contributes to the increased viscosity 
and adhesiveness of lung secretions. Recombi-
nant human DNase (rhDNase) liquefies the mu-
cus within minutes by hydrolysing extracellular 
DNA in mucus and transforms it from a viscous 
gel to a flowing liquid (3). Its nebulized use is ac-
cepted as an effective drug in the liquefaction of 
viscous mucus in patients with cystic fibrosis (3), 
and anecdotal evidence suggests a beneficial ef-
fect in other respiratory diseases, such as respira-
tory syncytial virus bronchiolitis (1,2) and atelec-
tasis due to mucus plugs (4-6).
Limited therapeutic options in newborns (es-
pecially preterms) with unresponsive atelecta-
sis created the need for a new treatment which 
would be safe and effective. The use of rhDN-
ase for the treatment of atelectasis in newborns 
is one of the new concepts. To our knowledge, 
there are only two reports on this issue, which 
included a total of 3 successfully treated patients 
(4,5). El Hassan et al (4) described the first case 
series of successful rhDNase treatment which in-
cluded 3 preterm neonates with atelectasis. Ku-
peli et al (5) reported an unsuccessful endotra-
cheal trial on a preterm baby with 29 weeks of 
gestational age. Beside these reports, Marcus et 
al (2) reported 2 mechanically ventilated infants 
with respiratory syncitial virus bronchiolitis just 
beyond newborn age. These patients were treated 
by nebulized rhDNase, upon which clinical and 
radiological parameters improved quickly. Be-
cause of limited data in newborns, there is a need 
to confirm the efficacy and safety of rhDNase 
treatment in a larger series.
We hypothesized that rhDNase would di-
minish atelectasis and mucus plugging in new-
borns with insufficient ability to clear thick and 
purulent airway secretions due to small airway 
caliber and ineffective cough mechanisms. We 
also aimed to evaluate clinical and radiological 
changes in newborns who received rhDNase for 
persistent atelectasis unresponsive to treatment 




Twelve newborns who did not respond to con-
ventional methods such as frequent positioning, 
chest physiotherapy, aspiration, selective endo-
tracheal suctioning, and medical treatment by 
salbutamol and N-acetylcysteine to release the 
mucus plugging were enrolled to receive rhD-
Nase. The therapy was explained to the parents, 
and informed consent was obtained from all 
families. Because rhDNase was administered as a 
part of patient’s treatment and not as a medical 
trial, formal approval from the local ethic com-
mittee was not required, and therefore was not 
requested.
Ten out of 12 patients were preterm. Gesta-
tional age of preterm patients ranged between 25 
to 37 weeks and birth weight between 760 and 
2250 g. Two term babies were postoperative pa-
tients who had birth weight of 3700 g and 3300 
g. Male to female ratio was 0.7 (5/7). Half of the 
patients were under mechanical ventilation when 
they developed atelectasis (Table 1).
Treatment
Patients received rhDNase (Pulmozyme®, Roche, 
Genentech Inc, San Francisco, CA, USA) nebu-
lized therapy at a dose of 1.25 mg twice daily (2 
hours between the doses) for up to 3 days. The 
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dose was based on the only successful report on 
preterm newborns by El Hassan et al (4). The 
drug was administered by a nebulizer (Aeroneb 
Professional Nebulizer System, Aerogen, Dan-
gan, Ireland) over 15 minutes. Two hours af-
ter the second dose, appropriate physiotherapy, 
frequent positioning, and suctioning were per-
formed to increase the drainage of the liquefied 
mucus. Chest radiogram was repeated two hours 
after the second dose to evaluate the efficacy of 
the drug. If the atelectasis improved the treat-
ment was terminated, otherwise the administra-
tion of the drug was continued for up to 3 days. 
After the three-day therapy, if there was no im-
provement in atelectasis, the drug was adminis-
tered as a single dose of 1.25 mg in a liquid form 
endotracheally.
Analysis
Gestational age, birth weight, sex, and primary 
diagnosis of all patients were recorded. After a 
complete physical examination, all patients had 
chest radiograms that demonstrated the local-
ization of the atelectasis. If needed, arterial blood 
gas analysis was performed before and after the 
last dose of the treatment.
Anteroposterior chest x-rays were coded 
and interpreted retrospectively by radiologists 
who were blinded to the study. A scoring system 
based on the available literature was used (7). It 
was based on the points for atelectasis, hyperin-
flation, and mediastinal shift. The presence or ab-
sence of hyperinflation and mediastinal shift was 
scored as 1 and 0, respectively. Atelectasis scor-
ing was performed for each lobe of the lung and 
a partial atelectasis was scored as 1 point, whereas 
a total atelectasis was scored as 2 points. These re-
sults were summed for each chest x-ray and the 
scores of the chest x-rays taken 2 hours after the 
treatment were compared with the scores before 
the treatment. Beside the radiological and arteri-
al blood gas response, all patients were evaluated 
clinically (respiration rate, requirement for oxy-
gen concentration), duration of the treatment, 
recurrence of atelectasis, and requirement of ad-
ditional therapy on follow-up.
Results
Ten out of 12 patients showed rapid clinical and 
radiological improvement after nebulized treat-
ment (Figure 1 and Figure 2). Two patients who 
did not respond to the three-day regimen re-
quired a single instillation of the drug endotra-
cheally and both of them recovered completely 
Table 1. Demographic and treatment data of the study group
Parameter Finding
Gestation week (median, range)   32 (25-39)
Birth weight (median, range) (g) 2187 (760-3700)
Sex (male/female)    5/7
On ventilator/no ventilator    6/6
Age during DNase treatment (median, range) (days)   11 (4-28) 
Duration of nebulized DNase treatment
 (median, range) (days)
   2.5 (1-3) 
Figure 1. rhDNase treatment resolved almost complete atelectasis. 
Left side total atelectasis in Case 8 responded to only one day regi-
men of rhDNase by a nebulizer.
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(Table 2). Half of the patients did not require 
completion of the three-day regimen for radio-
logical recovery. Two patients developed recur-
rent atelectasis; one a day and the other six days 
after the treatment. Both patients received a-
second-regimen of the drug by a nebulizer and 
recovered in two days. No adverse event was 
observed for both administration options of 
rhDNase.
Chest x-ray scores and respiratory parameters 
such as respiratory rate and oxygen requirement 
showed significant improvement after the treat-
ment (Table 3). Arterial blood gas analysis was 
obtained from 7 patients (6 of them were on me-
chanical ventilation) and comparison of pCO2 
before and after the last dose of nebulized rhDN-
ase showed significant improvement (Table 3).
Discussion
Six of our 12 patients were under mechanical 
ventilation and received nebulized rhDNase by 
an adaptor connected to the circuit. Riethmuel-
ler at al (8) reported that rhDNase treatment in 
mechanically ventilated children decreased the 
incidence of atelectasis, median ventilation time, 
median length of intensive care stay, and mean 
costs in patients. Excessive or thick pulmonary 
secretions are a common clinical challenge and 
the presence of mucus accumulation in a new-
born lung is a risk factor for pulmonary infection, 
Figure 2. Localization of percutaneous central venous catheter in 
Case 4 demonstrates the shift of the heart due to right total atelectasis 
(A); this case was on mechanical ventilation and treated by nebulized 
rhDNase for three days (B).



















1 RDS right total 28 3 + +
2 RDS left total 22 3 +
3 RDS right middle + 10 2
4 RDS+VAP right total +  7 3
5 RDS+VAP right upper +  9 3 +
6 HIE left total 12 2
7 RDS+VAP left upper + 14 2
8 RDS left total  9 1
9 RDS+VAP right upper +  4 1 + +
10 Congenital heart disease (postop) left total + 21 1
11 Cricopharyngeal achalasia right upper  6 3
12 RDS right total 24 3
*Abbreviations: RDS – respiratory distress syndrome; VAP – ventilator associated pneumonia; HIE – hypoxic ischemic encephalopathy.
Table 3. Change of radiological and respiratory parameters (me-
dian, range) of patients before and after the nebulized rhDNase 
treatment
Parameter Before treatment After treatment P
Chest X-ray score  4 (1-5)  0 (0-4) 0.005
Respiratory rate 66 (60-78) 49 (44-64) 0.002
O2 requirement (FiO2) (%) 45 (35-60) 30 (21-40) 0.005
pCO2* (mmHg) 56 (46-64) 41 (38-58) 0.018
*pCO2 was obtained from 7 newborns. 
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prolonged artificial ventilation, damage to the 
lungs and indirectly to other organs (4,9). Treat-
ment of atelectasis with chest physiotherapy or 
nebulized bronchodilator is not always effective, 
but the rescue use of rhDNase was reported to be 
effective in reestablishing airway patency. Its effi-
cacy has been well documented in cystic fibrosis, 
whereas case reports have described a beneficial 
effect in other respiratory disorders (2-5). Hen-
driks et al (7) reported that the use of rhDNase 
for atelectasis of presumably infectious origin in 
non-cystic fibrosis pediatric patients resulted in 
rapid clinical improvement within two hours 
and radiologic improvement in the large major-
ity of children within 24 hours. Sixteen patients 
in this study were younger than one year, and 
two were born prematurely, but were 6 and 7 
months of corrected age at the time of admission. 
The rhDNase dose was either 2.5 mg adminis-
tered twice daily with a jet nebulizer in children 
breathing spontaneously or 10% of that dose di-
luted with 5 mL NaCl 0.9% and given slowly as 
droplets into endotracheal tube during 30 min-
utes twice daily. The dose we used was equal to 
half of the dose in the study by Hendricks et al 
(7) and we administered the drug to all patients 
by nebulizer even when they were on mechani-
cal ventilation. Chest x-ray scoring that we used 
was similar to the study of Hendriks et al (7) and 
both studies showed marked improvement in 
chest x-ray scores and respiratory response. Nasr 
et al (1) used a different chest x-ray scoring in pa-
tients with RSV bronchiolitis but showed a sig-
nificant improvement in the chest x-ray with the 
use of nebulized rhDNase, compared with a sig-
nificant worsening in the placebo group.
There are only few case reports on rhDNase 
use in newborns. Merkus et al (2) administered 
2.5 mg nebulized dose of rhDNase twice daily to 
two mechanical ventilated infants just beyond 
newborn age and reported that following admin-
istration of nebulized rhDNase, clinical and ra-
diological parameters improved quickly. Kupe-
li et al (5) administered rhDNase of 0.2 mg per 
nebulizer endotracheally over 15 minutes, once 
a day for 5 days to a patient who was a preterm 
with 29 weeks of gestational age. They reported 
that mucus plugs were seen to liquefy in response 
to the drug, but even though frequent suctioning 
continued, profuse secretions created new atelec-
tatic areas (5). El Hassan et al (4) administered 
rhDNase as rescue treatment to three mechani-
cally ventilated preterms (two bronchopulmona-
ry dysplasia, one respiratory distress syndrome) 
and concluded that the rescue use of DNase was 
effective in reestablishing airway patency. This 
was the only series in newborns for rescue treat-
ment and our dose of nebulized rhDNase was 
based on this literature.
Our experience showed that this treatment 
option is safe and effective in newborns who do 
not respond to conventional treatments. Inhala-
tion of rhDNase seems to have no serious side ef-
fects. An increased incidence of voice alterations, 
laryngitis, pharyngitis, dyspepsia, and facial ede-
ma were reported in some patients in literature, 
but in our patients this was not the case (10).
After the three-day treatment, two patients 
needed to receive rhDNase in a liquid form en-
dotracheally in the same dose. We think that 
endotracheal instillation of rhDNase should be 
considered in cases of persistent atelectasis un-
responsive to nebulized treatment. Wills et al 
showed that rhDNase did not improve ciliary 
transportability (11). They postulated that grav-
itational drainage of the thinned mucus may be 
easier from the upper lobes. Newborn’s position 
does not permit the gravitational drainage so we 
speculate that chest physiotherapy and appro-
priate positioning of the baby may facilitate the 
drainage of the thinned mucus from the atelec-
tatic lobe.
To the best of our knowledge, this is the larg-
est published study on usefulness of rhDNase as 
a mucolytic agent in treating newborns with per-
sistent atelectasis who do not respond to other 
types of treatment. We conclude that our series 
with nebulized rhDNase demonstrates effective, 
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safe and easy therapeutic option for use in treat-
ing persistent atelectasis in newborns on the ba-
sis of clinical and radiological improvement. Al-
though the results of our series are promising, 
the study was limited with a small number of pa-
tients, retrospective nature of the study, and the 
lack of a comparison, so that further randomized 
controlled trials are needed to confirm our results 
and investigate the clinical changes under appro-
priate dosage of this drug.
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